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Introduction
The unprecedented scale and content of genomic
and proteomic information now emerging from
global sequencing and analysis efforts offer new
opportunities in biological research. Technological
and computational developments have enabled ﬁrst
phase analytical platforms for genomic and pro-
teomic studies. However, the ultimate goal will
be to integrate data from diverse analytical plat-
forms, so that biological systems can be modelled
with increasing complexity to achieve understand-
ing at the systems level. The new techniques
of microarray technology and high-throughput
screening (HTS) proteomics are already providing
new insights into cell form and function. These
approaches are poised to revolutionize much of
biological research methodology, but will require
the increasing fusion of biological sciences with
mathematics, computing and physical sciences to
generate platform technologies and approaches for
the speciﬁc and HTS analysis of biological pro-
cesses. This workshop was held to review the cen-
tral role of bioarrays in genomic and proteomic
studies and to examine their potential for future
applications. It was also critical to consider the
requirement for bioinformatic and computational
tools and methods to enable rational handling and
interpretation of data.
This event was organized as a research workshop
under the auspices of the Royal Society of Edin-
burgh and the Wellcome Trust. The report below
considers the three major bioarray-related themes
resulting from the meeting: analytical methods;
functional genomic applications and the develop-
ment of new technologies. These key areas will
require fusion to provide a fuller understanding of
biological systems (Figure 1).
Analytical methods: the statistics behind
bioarray analysis
Claus Mayer (Rowett Research Institute, Aberdeen,
and BIOSS, Edinburgh, UK) emphasized the
role of statisticians in microarray technology and
research. He pointed out that cooperation between
statisticians and biologists is useful and proﬁtable
for both sides. Although the number of purely
statistical papers on microarray technology has
grown exponentially, they are still in a minority
compared to microarray-related biology papers.
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Figure 1. Fusions required for systems biology
This indicates, however, that statistical methods
would continue to impact in microarray research.
Statisticians should make use of the opportunity
to develop ideas and models for analysing
images and data structures (amount of data,
dimensionality, sources of noise and variation)
that are different from ‘traditional’ approaches.
Despite this complexity, the actual background
and implications behind microarray technology are
still easier to understand than most other areas
of biology. Biologists should make use of the
opportunity to apply structured analysis methods
and approaches to microarray data, resulting in
greater conﬁdence in their numerical results. This
in turn will produce a better foundation for
biological interpretations. He listed the areas in
which statistics can be utilized in microarray
research: experimental design; image processing;
transformation/normalization; and single gene and
multivariate analysis. In view of this, it is beneﬁcial
to involve statisticians early on in the planning
of a microarray project. In terms of practical
recommendations for the processing of microarray
data, he outlined the following:
• Estimation of systematic background trends
might be preferable to subtracting individual
backgrounds.
• Replication is required at all experimental levels.
• Log-transformations to be carried out on ratio
data and absolute values, or alternatively, gamma
or arcinh transformations can be applied.
• Normalization methods need to be decided on a
per-experiment basis.
• Investigation of distributions and histograms
should be part of the analysis process.
Concluding, he pointed out that statistical meth-
ods should be integrated with bioinformatics and
other technologies and approaches for the complete
analysis of microarray data.
John Quackenbush (Institute for Genomic Re-
search, TIGR, Rockville, USA) discussed practi-
cal approaches in the analysis of microarray data.
He pointed to the important relationship between
study design and data normalization and analysis.
The collation of as much information as possi-
ble about the experiment is required. Ideally, this
information would adhere to the MIAME standards
discussed by Brazma (below). He compared a stan-
dard microarray reference design to the loop-design
concept and pointed out their advantages and dis-
advantages. Reference design is simple, robust
and easily extensible, but provides limited data
for experimental samples. Loop designs provide
better statistics and direct cross-sample compar-
isons, but they demand a larger amount of bio-
logical material for analysis and are not as robust.
Overall, loop designs are preferable over reference
designs if properly formulated. Basic experimen-
tal design should include independent biological
replicates incorporating self-to-self comparisons or
‘dye-swap’ experiments. A number of approaches
for dye-effect normalization were put forward. The
essential requirement is to perform normalization
or a combination of normalization methods ini-
tially; and that the particular method should be
decided on a per-experiment basis. Whether global
or gene subset normalization is employed depends
on the experimental design and array layout. As
a useful method of visualizing the relationship
between dye-effect and the magnitude of expres-
sion measurements he suggested the R–I plot
[log2(R/G) vs. log10(R∗G)], which is closely related
to the M–A plot suggested by Terry Speed’s group
(UCLA, Berkeley, USA).
An explanation of the ideas behind various
types of cluster analysis to measure the similarity
of expression proﬁles for genes was given. No
general recommendations of the best parameter
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choices or clustering approach can yet be made.
This is because all types and methods have their
own features and highlight different aspects of the
underlying data. Concluding, he pointed out that,
apart from microarray technology, there is a wealth
of information emerging from all genomic and
related technologies. The challenge is to combine
these data sets to gain a deeper insight into
biological processes. However, it was pointed out
that additional layers of data demand increasing
caution when inferring biological signiﬁcance from
statistical signiﬁcance. The role of the biologist will
continue to be essential in all stages of design,
analysis and interpretation. During the course of his
talk, some of the computational and bioinformatic
tools TIGR (http://www.tigr.org/software/) and
others have developed were presented:
• GENE INDEX (integration of several databases,
EST data including a variety of tools for ortho-
logue and paralogue mapping).
• RESOURCERER (annotation tool and resource
comparison based on TIGR Gene Index).
• MEV (multi experiment viewer, data normaliza-
tion, analysis and visualization tool).
• MADAM (microarray data manager, under deve-
lopment).
• MIDAS (microarray information and data ana-
lysis suite, under development).
• ANOVA (statistical tools, TIGR/Jackson Labo-
ratories).
• MAD (downloadable database of in-house mic-
roarray experiments on mouse genome, Jackson
Laboratory).
Andy Brass (University of Manchester, UK) pre-
sented ideas for the use of gene expression distri-
bution on a per-chip basis. In contrast to examining
expression of individual genes across conditions or
time-points, this approach concentrates on global
gene expression across entire arrays or genomes.
He identiﬁed four features that, if monitored, could
be used for quality control and data normalization:
• Microarray data usually demonstrate log-normal
distribution.
• Microarray data ﬁt Benford’s law fairly well, i.e.
one can expect 1 to be the ﬁrst logscale digit of
an intensity value in about 30% of cases, 2 will
come up in about 18% of cases, 3 in 12%, etc,
so that [P(D) = log10(1 + D−1)].
• Microarray data also appear to ﬁt Zipf’s law,
which states that the quantity under study is
inversely proportional to the rank, i.e. propor-
tional to 1, 1/2, 1/3, etc. Therefore, if using logs
of value and rank, if the highest expression (rank
1) is 10, then the second highest expression is
10–log(2), third highest 10–log(3), etc.
• Microarray data appear to show a relationship
between width of distribution and size of genome
under study.
Knowing what characteristics the data distribu-
tion on an array conform to might facilitate qual-
ity control and normalization by comparing and
adjusting the actual distribution to these rules. It
is possible that the biological signiﬁcance of these
phenomena is related to the average number of
transcription factor binding sites per gene. In sum-
mary, it was proposed that signal intensity distribu-
tions for an array are based on real biology, and that
biology as well as data can be successfully mod-
elled by log-normal distributions. This could prove
to be the basis for useful QC and normalization
tools. Options for this type of data processing will
be included in a new release of the MaxD microar-
ray data warehouse and visualization environment.
Alvis Brazma (EMBL-EBI, Cambridge, UK)
presented a discussion of microarray data stan-
dards, databases and data mining, which explored
some of the challenges inherent in both the biolog-
ical and computational complexity of microarray
experiments. Setting the scene, he ﬁrst described
the various elements and operations that together
comprise microarray experiments. The scale and
complexity of the data required to describe and
record such experiments, the protocols used in them
and the expression data they produce raise ques-
tions about how to assess the quality and rele-
vance of data for the interpretation of experimental
results. One approach is to implement standardiza-
tions of data capture and analysis as an approach to
reduce the scale and complexity of data recorded
for each microarray experiment. However, stan-
dardization is challenging and requires consistent
and coherent procedures for gene annotation, con-
sistent data exchange formats and continuity of
experimental measurements. To meet these chal-
lenges, the Microarray Gene Expression Data
(MGED) group has been introduced to estab-
lish consensus and common practice in the areas
of information content, data exchange formats,
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biological sample ontologies and data normal-
ization strategies. The ﬁrst of these standard-
ization efforts, the Minimum Information About
a Microarray Experiment (MIAME), was intro-
duced and the scope of its application, includ-
ing sample identiﬁcation, extraction, labelling and
hybridization, was outlined. Description was given
of the publicly available MIAMExpress and Array-
Express tools as reference implementations of
the MIAME standardization effort. Finally, a
description of Expression Proﬁler and other com-
putational tools for the analysis, visualization
and interpretation of microarray gene expression
data was given (for applications described, see:
(http://www.ebi.ac.uk/microarray/index.html)
From genes to function
Dr Phil Butcher (SGHMS, London, UK) described
the multi-user bacterial pathogen array facility
based at St. George’s Medical School, London
(http://www.sghms.ac.uk/depts/medmicro/bugs/
bugs content frame.htm). This is a Wellcome
Trust-funded initiative to provide DNA microar-
rays for a range of pathogenic bacteria. Functional
genomics requires the fusion of different analyt-
ical platforms, such as genomics, proteomics and
metabolomics, for the full analysis of complex bio-
logical systems, e.g. the interplay between host and
pathogen during bacterial infection. The primary
aim of the unit at St. George’s is the produc-
tion of DNA microarrays for several pathogenic
bacteria. Arrays are fabricated using speciﬁc short
PCR probes generated using speciﬁcally designed
primers to bacterial gene sequences. The main
focus of the talk was the application of genomic
and proteomic technologies in the analysis of
Mycobacterium paratuberculosis physiology. M.
paratuberculosis is the causative agent of tuber-
culosis (TB), the worldwide incidence of which
continues to increase. The development of an array
platform for the genome of this organism was
described. The array has been useful for compara-
tive genotyping of M. paratuberculosis strains and
mutants, and this HTS genotyping approach will be
generally applicable to other bacterial pathogens.
Examples of RNA transcriptional proﬁling exper-
iments using the array were also given. However,
there are signiﬁcant experimental problems asso-
ciated with the analysis of bacterial RNA. For
instance, 98% of bacterial RNA is ribosomal, lead-
ing to problems in generating sufﬁcient yields of
messenger RNA. Bacterial RNA is notoriously
labile (average half-life typically less than 2 min)
and very prone to degradation during extraction. In
addition, bacterial transcripts are extremely tightly
regulated, and there are very rapid switches in
transcription proﬁles in response to changing envi-
ronmental or physiological conditions. Bacterial
messenger RNA is not polyadenylated, so gene-
speciﬁc priming is usually employed during the
target labelling step. Lysis of bacteria can be
problematic and time consuming and may gen-
erate contaminants, which must be subsequently
removed. These problems will require improve-
ments in experimental methods for sample prepa-
ration and labelling. Nevertheless, examples were
given of the microarray gene expression proﬁle of
M. paratuberculosis in response to stress condi-
tions in vitro and during infection in vivo. A range
of similar problems is encountered in proteomic
analysis involving sampling and extraction of bac-
terial proteins for 2D gel separation and mass spec-
troscopic analysis. In both genomic and proteomic
studies, very consistent methods of experimenta-
tion, including rapid processing, must be developed
and adhered to.
Keith Vass (CRC Beatson Institute, Glasgow,
UK) described the microarray-related research
under way at the Beatson Institute. Signiﬁcant
research activity is concentrated on collaborative
projects using the microarray platforms, exper-
imental samples and approaches from the M.
paratuberculosis research consortium described by
Phil Butcher (see above). The need for appropriate
tools for data normalization and visualization to
analyse these experiments correctly was outlined.
An ANOVA-based program has been developed
in conjunction with the Department of Statistics
at Glasgow University that accounts for the many
sources of variation in microarray experiments and
uses the background signal for the correction of
spatial effects on the array. In order to classify
operon usage during M. paratuberculosis growth
proﬁle experiments, analysis of co-variance and
correlation maps of expression from adjacent genes
were used. This approach should indicate func-
tional relationships useful for the global mapping
of operon activity.
Tom Freeman (HGMP-RC, Cambridge, UK)
described the activities of the microarray unit at
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the MRC-HGMP resource centre based at Hinx-
ton, Cambridge (http://www.hgmp.mrc.ac.uk/
Research/Microarray/index.jsp). This unit has
been set up by strategic funding from the MRC
and other agencies to provide access to array tech-
nology for academic researchers within the UK.
The unit provides training and support protocols for
DNA microarray applications, and the design and
fabrication of new array sets. The unit also pro-
vides access to the Affymetrix Gene Chip System.
The remit of the unit is the dissemination of human
and mouse arrays to the academic community.
These will be free of charge, but prior application
is required. The unit holds several large PCR-
based probe sets, which are ampliﬁed using high-
throughput robotics available at HGMP. These are
arrayed onto glass slides, most usually via amino
linkage. A number of control probes are added,
including a range of spiking controls for genes con-
sidered suitable for microarray normalization. The
quality of PCR libraries is of critical importance,
and those used by HGMP are sequence-veriﬁed
and well curated to reduce insert or phage con-
tamination errors. However, the logistical problems
associated with PCR based arrays were highlighted.
The main problem is the consistent re-ampliﬁcation
of large clone sets to the required concentration and
speciﬁcity. This process incurs considerable cost
in terms of materials, time and personnel. There
are other problems concerned with PCR arrays,
including availability of probe sets and potential
speciﬁcity.
Consequently, long oligonucleotide probes are
ﬁnding increasing favour for the construction of
DNA microarrays. Currently, oligos in the region
of 50–70 mer are speciﬁcally designed to represent
genes of interest. Although relatively expensive to
procure as a one-off set, oligomer-based arrays can
be produced with a high level of accuracy and
consistency. A major beneﬁt of oligomers is the
speciﬁcity and accuracy of probe design, which
will become increasingly sophisticated to gener-
ate exon-speciﬁc probes for multigene families and
the detection of splice variants. The HGMP have
access to a number of mammalian oligo probe sets,
and genome-wide sets are under development. Also
highlighted was the development of a database and
LIMS architecture dedicated to the activities of
the unit. Finally, Dr Freeman drew attention to a
number of considerations important for success-
ful array projects. These include the importance
of experimental design and deﬁnition of the bio-
logical system under consideration. Experiments
should include biological replicates and the quality
of the data depends on the selection of consistent
and high quality arrays to be used, in conjunction
with effective and well-characterized experimental
protocols. Data should be compared to the literature
and veriﬁed by independent means where possible.
The consistent management of data and the consid-
eration of MIAME standards will be a prerequisite
for publication.
Steve Kay (The Novartis Research Foundation,
Scripps Institute and Phenomix, San Diego, USA)
began his presentation by reviewing current tech-
nologies for biological analyses at a molecular,
cellular and organismal level and proceeded to
describe his work on the construction of an RNA
expression atlas at the Novartis Foundation. The
Atlas project has involved a programme of tran-
scriptional proﬁling in 50 human and mouse tissues
using the Affymetrix GeneChip platform. Profes-
sor Kay highlighted the reassuring discovery that,
in general, organ-speciﬁc expression proﬁles are
very similar in humans and mice. It is likely
that the expression atlas will become an important
resource in the future and data from this study will
soon be available at (http://expression.gnf.org).
Indeed, the atlas has already been used to derive
the molecular signatures of many commonly fatal
carcinomas.
Professor Kay proceeded to describe his aca-
demic work on circadian rhythms in nature, under-
taken at The Scripps Research Institute. Global
gene expression proﬁling studies have demon-
strated that hundreds of genes are ‘clock’-regulated
and cycle throughout a 24 h period in a vari-
ety of organisms. An example of such a gene is
that which encodes the phenylpropanoid enzyme
in plants. It was pointed out that three independent
studies in this ﬁeld, all attempting to identify clock-
regulated genes, have only identiﬁed 16 genes in
common. This indicates that even if a careful exper-
imental design and a structured approach to data
analysis are adopted, subtle differences in strat-
egy may yield notably different answers. Examples
of the tissue-speciﬁc control of clock gene expres-
sion were given, e.g. microarray experiments have
demonstrated that the SCN master oscillator in the
brain controls the ‘rhythm’ of gene expression in
the liver.
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Finally, there was description of a mouse forward
genetics project carried out with the company
Phenomix. This project has involved a genome-
wide mutagenesis and screening program, which
aims to identify genes involved in neurological,
immunological and physiological processes and
disease states. This screening process has exploited
a novel high-throughput antibody array system
for serum proﬁling. The antibody array has the
capability to simultaneously measure up to 96
analytes in less than 20 µl serum and can be used
to screen more than 200 mice per week. This
technology has allowed great advances in parallel
biological and mapping analyses.
Douglas Roy (SCGTI, Edinburgh, UK) rein-
forced that biology increasingly requires HTS
experimental and analytical methods to accom-
modate the scale and complexity of genomic
and proteomic information now available. The
Scottish Centre for Genomic Technology and
Informatics was introduced as an example of
how a centralized approach incorporating genomic
technologies and bioinformatics can address the
requirements for functional genomic analysis. The
SCGTI (http://www.gti.ed.ac.uk) operates as a
major collaborative focus for the application of
genomic technologies combined with statistical,
bioinformatic and computational methods for data
handling and visualization. The SCGTI collabo-
rates on a wide range of projects covering mam-
malian systems, model organisms and pathogens.
Several examples of the types of projects under
way were outlined. For these projects, a variety
of DNA and protein microarrays are fabricated in
house, and the Centre also utilizes the Affymetrix
Gene Chip system. There is close collaboration
with groups wishing to apply microarray analy-
sis to biological problems. A number of novel
genomic and proteomic array platforms are under
development, including the analysis of splice vari-
ants in yeast, genomic structural studies and the
detection of blood typing proteins. The SCGTI is
developing a relational database architecture based
on the NCGR GeneX schema to accommodate the
data analysis and LIMS requirements of collabo-
rating research groups. A future aim of the Cen-
tre will be the incorporation and integration of
diverse data sets (genomics, proteomics and imag-
ing) to model biological systems in greater com-
plexity.
Emerging technologies
Jon Cooper (University of Glasgow, UK) discussed
the impact of nanotechnology on drug discovery.
An overview was given of the relative scale and
manufacturing processes required for the produc-
tion of ﬁeld effect transistors. Discussion then fol-
lowed of the advantages of nanotechnologies and
how they might be applied to biomedical research.
Description was given of micro-ﬂuidic systems,
which allow the highly controlled ﬂow and mixing
of minute quantities of liquids. An overview was
given of his work on a micro-machined chip for
DNA hybridization studies and the development of
micro- and nano-sensors for the study of intracellu-
lar metabolic activity. In particular, he highlighted
a system for the study of thermal measurements in
single cardiomyocyte cells following exposure to
a variety of environmental changes. Finally, recent
studies undertaken in conjunction with the com-
pany Adaptive Screening were described. These
studies have focused on the development of novel
high-density cell-screening devices. Such devices
can be used for ultra-high-throughput cell-based
functional assays.
Tony Cass (Imperial College, London, UK) out-
lined the challenges facing the high-throughput
analysis of protein interactions. It is predominantly
proteins that impart form and function to living
systems, and protein binding is the key biologi-
cal event inherent to signalling and transmission.
Human genomic analysis currently predicts 35 000
genes coding for around 150 000 proteins. At one
level of analysis, the proteome can be considered
as a matrix of 150 000 protein-binding sites. How-
ever, there are problems in the development of
HTS proteomic platforms for protein interaction
studies. Thus, far fewer than 1% of proteins are rep-
resented in protein databases, with new additions
running at approximately 1000 per annum. Pro-
teins are classiﬁed into subfamilies and no method
exists for global protein interaction analysis sim-
ilar to those used in the microarray analysis of
nucleic acids. This poses a problem for pharma-
ceutical research where, despite an explosion of
information about potential genetic targets and the
generation of comprehensive compound libraries
for analysis, there has not been a commensurate
increase in lead compound discovery and target val-
idation. Existing methods of compound validation
are proving increasingly costly, due to the failure
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Figure 2. Deﬁnition of functional genomics
to identify non-speciﬁc binding during the valida-
tion process. A failure rate of up to 90% during
validation can occur, and this has driven the devel-
opment of advanced HTS proteomic methodologies
to overcome this bottleneck.
A new approach from Adaptive Screening (http:-
//www.adaptive-screening.com) termed the Surro-
gate ProteomeTM, was introduced as an HTS plat-
form technology for detecting protein–ligand bind-
ing signatures during drug discovery and devel-
opment. This involves the construction of high-
density arrays of ﬂuorescently labelled protein scaf-
folds containing a spectrum of binding sites reac-
tive to many drug compounds. The labelled protein
scaffolds act as monitors for the binding of speciﬁc
ligands, which are detected using proprietary low-
light readers. The aim is to create diversity within
protein-binding space. The binding signature of a
ligand is monitored against known standards and
its speciﬁcity can be determined. The ‘ASETM’
bioinformatics platform is used to provide databas-
ing, LIMS and predictive decision-making func-
tions with the system.
Conclusions
Peter Ghazal (Director, SCGTI, Edinburgh, UK)
concluded the meeting by highlighting the oppor-
tunities for the new methods and systems under dis-
cussion during the meeting to advance our under-
standing of biological systems. By deﬁnition, the
emerging ﬁeld of post-genomics embraces a fully
integrative approach to mapping the near totality
of DNA content with gene and protein activities
(Figure 2). Bioarray technology is a fast-maturing
science that will continue to deliver highly parallel
data of an increasingly speciﬁc nature. This will
impact not only academic biomedical research but
also the pharmaceutical, biotechnology and health-
care sectors. Of critical importance will be the con-
tinued integration of bioinformatics and databasing.
Opportunities lie ahead to generate sophisticated
HTS methods to explore new areas. The poten-
tial and possibilities for bioarray and microﬂuidic
applications seem almost limitless. Much work and
interdisciplinary fusion will need to take place to
realise this enormous potential. This meeting was
valuable not only to reveal these concepts, but also
to discuss future challenges and potentials. The
meeting was well received and considered a suc-
cess by the participants. Particularly appreciated
was the diversity and quality of the presentations.
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